Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger von Moos

Showing results (1-10 of 123) with videos related to

Pageof 13
Sort By:
The Oncologist|November 3, 2005
Bisphosphonate treatment recommendations for oncologistsRoger von Moos
Journal of Clinical Medicine|August 4, 2015
Where Do Bone-Targeted Agents RANK in Breast Cancer Treatment?Roger von Moos, Ian Haynes
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|February 7, 2012
Denosumab: first data and ongoing studies on the prevention of bone metastasesRoger von Moos, Tomas Skacel
Revue Medicale Suisse|December 18, 2015
[Is prescription of a therapy costing 150,000 CHF reasonable?]Solange Peters, Roger von Moos, Beat Thurlimann
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 3, 2009
Intratumoral therapy with interferon-alpha in a locoregional advanced malignant blue nevus: a brief communicationRoger von Moos, Reto Schaffner, Richard Cathomas, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 7, 2008
Metastatic bone pain: treatment options with an emphasis on bisphosphonatesRoger von Moos, Florian Strasser, Silke Gillessen, et al.
Swiss Medical Weekly|March 20, 2003
Thalidomide: from tragedy to promiseRoger von Moos, Rahel Stolz, Thomas Cerny, et al.
Onkologie|October 8, 2010
Spontaneous pneumothorax during chemotherapy: a case reportMartin Fehr, Roger von Moos, Markus Furrer, et al.
Lung Cancer (Amsterdam, Netherlands)|July 22, 2016
Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: Report of two casesYannis Metaxas, Richard Cathomas, Michael Mark, et al.
Hematological Oncology|September 20, 2016
Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutationUlrich J M Mey, Christoph Renner, Roger von Moos
Pageof 13

Showing results (1-10 of 123) with videos related to

Sort By:
Pageof 13
The Oncologist|November 3, 2005
Bisphosphonate treatment recommendations for oncologistsRoger von Moos
Journal of Clinical Medicine|August 4, 2015
Where Do Bone-Targeted Agents RANK in Breast Cancer Treatment?Roger von Moos, Ian Haynes
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|February 7, 2012
Denosumab: first data and ongoing studies on the prevention of bone metastasesRoger von Moos, Tomas Skacel
Revue Medicale Suisse|December 18, 2015
[Is prescription of a therapy costing 150,000 CHF reasonable?]Solange Peters, Roger von Moos, Beat Thurlimann
Journal of Immunotherapy (Hagerstown, Md. : 1997)|December 3, 2009
Intratumoral therapy with interferon-alpha in a locoregional advanced malignant blue nevus: a brief communicationRoger von Moos, Reto Schaffner, Richard Cathomas, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|August 7, 2008
Metastatic bone pain: treatment options with an emphasis on bisphosphonatesRoger von Moos, Florian Strasser, Silke Gillessen, et al.
Swiss Medical Weekly|March 20, 2003
Thalidomide: from tragedy to promiseRoger von Moos, Rahel Stolz, Thomas Cerny, et al.
Onkologie|October 8, 2010
Spontaneous pneumothorax during chemotherapy: a case reportMartin Fehr, Roger von Moos, Markus Furrer, et al.
Lung Cancer (Amsterdam, Netherlands)|July 22, 2016
Combination of cisplatin and lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma: Report of two casesYannis Metaxas, Richard Cathomas, Michael Mark, et al.
Hematological Oncology|September 20, 2016
Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutationUlrich J M Mey, Christoph Renner, Roger von Moos
Pageof 13